Ipsen beefs up in oncology, buying US biopharma Epizyme
pharmaphorum
JUNE 27, 2022
The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.
Let's personalize your content